Emerging Longevity Research: Reprogramming, Gene and Cell Therapies

Partial reprogramming

Reprogramming means briefly switching on a few genes (the "Yamanaka factors") to push cells toward a younger state without turning them into stem cells.

• Mice with premature aging. Short, repeated expression of four factors (OSKM) eased signs of aging and prolonged lifespan in a mouse model of premature aging; it also improved recovery from metabolic disease and muscle injury in older normal mice. [1][2] Label: preclinical (cells or animals only).
• Older normal mice. A review describes a gene-therapy version in which delivery of three factors extended the remaining lifespan of 124-week-old wild-type mice by 109% compared with untreated mice. [3]
• Human cells in the lab. Reviewers note that partial reprogramming can reverse an epigenetic clock in vitro. [4] A clock is a measurement, not a health outcome; see epigenetic clocks and DNA methylation.

Known problems. In one cited mouse study, twelve days of OSKM expression in the heart proved lethal. [5] Reviewers also describe possible cancer risk, from epigenetic changes and from higher mutation rates seen during full reprogramming to stem cells. [6] Delivery to the right tissue is limited by low efficiency and insufficient organ specificity. [7]

The first human trial

A phase 1 trial (NCT07290244) of a gene therapy called ER-100, sponsored by Life Biosciences, [8] began in March 2026 [9] in adults with optic nerve conditions, namely open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. [10][11] It is a non-randomized safety study with dose escalation, and participants are to be followed for up to 5 years. [12][13][14] The ClinicalTrials.gov record describes the goal as safety and tolerability. [11]

An October 2026 report relaying a company announcement says interim data from three participants showed the treatment was well tolerated through day 56, with no serious adverse events, and "preliminary signals" of better visual field testing in two. [15][16][17] That is a company-reported interim result, not yet peer reviewed in anything we read, and it concerns an eye disease. Label: insufficient evidence for any benefit, and nothing about aging in the whole body.

Telomerase gene therapy

In a 2012 mouse study, a virus carrying the telomerase gene increased median lifespan by 24% (treated at 1 year) and 13% (at 2 years) without more cancer than control littermates. [18] Label: preclinical (cells or animals only). Human evidence: Proper evidence not found in the sources we read. Telomere tests are in telomeres and aging.

Cell therapy for frailty

Frailty is a condition of reduced reserve in older people, studied separately from aging itself (see frailty). A 2024 phase I/II randomized, double-blind, placebo-controlled trial tested umbilical cord stem cells in people with aging frailty and reported improvement in a quality-of-life score from the first visit. [19][20] A 2026 systematic review found only three randomized trials with about 208 participants; the treatment was well tolerated with no treatment-related serious adverse events, but trial size, cell source, dose, endpoints and follow-up differed. [21][22][23] Label: promising but limited for frailty in a trial setting; insufficient evidence for aging.

Reading news about these therapies

Ask whether it is a mouse study, a human trial, or a company announcement; what disease was treated; and what outcome was measured. See reading longevity studies and longevity research limitations.